Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults

Reuters

Yesterday

Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults

Vaxcyte Inc. has announced the initiation of the OPUS-3 Phase 3 clinical trial evaluating VAX-31, the company's 31-valent pneumococcal conjugate vaccine candidate, in adults previously vaccinated with lower-valency pneumococcal vaccines. The trial will assess the safety, tolerability, and immunogenicity of VAX-31, including its ability to boost serotype-specific immune responses and broaden coverage in this adult population. The OPUS-3 trial is part of Vaxcyte's comprehensive Phase 3 adult clinical program, which also includes the OPUS-1 pivotal noninferiority trial and the OPUS-2 trial evaluating concomitant administration with a seasonal influenza vaccine. Topline data from the OPUS-3 and OPUS-2 trials are expected in the first half of 2027, while results from the OPUS-1 trial are anticipated in the fourth quarter of 2026. No clinical trial results have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653128-en) on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610880966"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610880966\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610880966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610880966","market":"nz","top_or_hot":-1,"title":"Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte Inc. has announced the initiation of the OPUS-3 Phase 3 clinical trial evaluating VAX-31, the company's 31-valent pneumococcal conjugate vaccine candidate, in adults previously vaccinated with lower-valency pneumococcal vaccines. The trial will assess the safety, tolerability, and immunogenicity of VAX-31, including its ability to boost serotype-specific immune responses and broaden coverage in this adult population. The OPUS-3 trial is part of Vaxcyte's comprehensive Phase 3 adult clinical program, which also includes the OPUS-1 pivotal noninferiority trial and the OPUS-2 trial evaluating concomitant administration with a seasonal influenza vaccine. Topline data from the OPUS-3 and OPUS-2 trials are expected in the first half of 2027, while results from the OPUS-1 trial are anticipated in the fourth quarter of 2026. No clinical trial results have been presented yet.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653128-en) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte Inc. has announced the initiation of the OPUS-3 Phase 3 clinical trial evaluating VAX-31, the company's 31-valent pneumococcal conjugate vaccine candidate, in adults previously vaccinated with lower-valency pneumococcal vaccines. The trial will assess the safety, tolerability, and immunogenicity of VAX-31, including its ability to boost serotype-specific immune responses and broaden coverage in this adult population. The OPUS-3 trial is part of Vaxcyte's comprehensive Phase 3 adult clinical program, which also includes the OPUS-1 pivotal noninferiority trial and the OPUS-2 trial evaluating concomitant administration with a seasonal influenza vaccine. Topline data from the OPUS-3 and OPUS-2 trials are expected in the first half of 2027, while results from the OPUS-1 trial are anticipated in the fourth quarter of 2026. No clinical trial results have been presented yet.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653128-en) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL9FSYx9:1","article_id":"2610880966","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610880966","pubTimestamp":1770843928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vaxcyte Inc. has announced the initiation of the OPUS-3 Phase 3 clinical trial evaluating VAX-31, the company's 31-valent pneumococcal conjugate vaccine candidate, in adults previously vaccinated with lower-valency pneumococcal vaccines. The trial will assess the safety, tolerability, and immunogenicity of VAX-31, including its ability to boost serotype-specific immune responses and broaden coverage in this adult population. The OPUS-3 trial is part of Vaxcyte's comprehensive Phase 3 adult clinical program, which also includes the OPUS-1 pivotal noninferiority trial and the OPUS-2 trial evaluating concomitant administration with a seasonal influenza vaccine. Topline data from the OPUS-3 and OPUS-2 trials are expected in the first half of 2027, while results from the OPUS-1 trial are anticipated in the fourth quarter of 2026. No clinical trial results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","PCVX":"Vaxcyte, Inc.","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技"},"translate_title":"Vaxcyte开始在先前接种过疫苗的成人中进行VAX-31肺炎球菌疫苗的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":0.9,"NDAQ":0.9},"content_text":"Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults\n    \n\n        Vaxcyte Inc. has announced the initiation of the OPUS-3 Phase 3 clinical trial evaluating VAX-31, the company's 31-valent pneumococcal conjugate vaccine candidate, in adults previously vaccinated with lower-valency pneumococcal vaccines. The trial will assess the safety, tolerability, and immunogenicity of VAX-31, including its ability to boost serotype-specific immune responses and broaden coverage in this adult population. The OPUS-3 trial is part of Vaxcyte's comprehensive Phase 3 adult clinical program, which also includes the OPUS-1 pivotal noninferiority trial and the OPUS-2 trial evaluating concomitant administration with a seasonal influenza vaccine. Topline data from the OPUS-3 and OPUS-2 trials are expected in the first half of 2027, while results from the OPUS-1 trial are anticipated in the fourth quarter of 2026. No clinical trial results have been presented yet.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653128-en) on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}